Immunai is building a Google Maps of the immune system using AI and biological data to better understand why some patients respond to treatment while others don’t.
Public source
Publisher name
Public post
“We’re building a Google Maps of the immune system.” That’s how our Associate Director of Computational Biology, Alon Shaiber, described the work we’re doing at Immunai…
Company
Immunai
Mapping the Immune System with AI to Improve Health
- Industry
- Biotechnology Research
- Location
- New York, US
- Company size
- 51–200 employees
About Immunai
Comprehensively mapping and decoding the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes
See moreLatest activity
Latest activity from Immunai
4 signals
Presence & Recognition
Immunai is attending ESMO 2026 in Madrid from October 23 to 27, speaking about AMICA-OS and its role in transforming immune complexity into clarity for drug development decisions.
Products & Services
Immunai spoke with CTech by Calcalist about how Immunai is governing agentic AI with a visibility platform, a kill switch on every workflow, and a human approval gate on identity, access, or production.
Research & Knowledge
Immunai is working with Calcalist to combine AI with biological data to help pharma understand why some patients respond to treatment while others don’t and turn insights into better drug development decisions.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Tempus AI
Tempus AI is developing a living data model that connects biological data to its source, normalizes it, and uses AI to answer new questions as they arrive.
Research & Knowledge
LurexBio
LurexBio is focused on immune recognition and how improved recognition could help the immune system identify cancer cells more effectively.
Research & Knowledge
Alithea Bio
Alithea Bio released the HLA-Compass database, the largest immunopeptidomics resource available, to help teams develop better neoantigen cancer vaccines.
Research & Knowledge
Cure51
Cure51 published a Rosalind Study combining multiple layers of patient data, including genomics, transcriptomics, pathology, clinical history, and multi-omics insights, to integrate complex datasets and identify patterns for AI-driven treatment prediction.
Research & Knowledge
ViewsML